# Dissecting Oligogenic Biomarkers in Ashkenazi Jews with Parkinson Disease

> **NIH NIH U01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $1,241,583

## Abstract

ABSTRACT: Despite gains made in symptomatic therapies for Parkinson Disease (PD), disease-modifying
trials have not been successful. Discovering genetic biomarkers that identify heterogeneity among disease
states and subgroups facilitates logistics of trial design and inspires targets for intervention. Several lines of
evidence indicate that current classification schema using PD single gene subgroups only are inadequate and
do not fully reflect the spectrum of clinical etio-pathology, including growing evidence for oligogenic
mechanisms. Thus there is a need to identify additional genes and contributing genetic biomarkers. These
may help in the development of a composite score, similar to practice in oncology whereby multiple genetic risk
factors are assessed in therapeutic decision-making.. Herein, we strive to elucidate blood-based genetic
biomarkers through evaluation of individuals of Ashkenazi Jewish (AJ) background. In addition to a higher rate
of PD and increased frequency of LRRK2 and GBA mutations, these individuals are characterized by genetic
homogeneity and founder effects that may facilitate elucidation of disease-related genes with much smaller
sample sizes. This is now a pivotal moment in PD disease modifying trials as agents directed at GBA related
targets and LRRK2 mediated therapies are either underway or in planning. In Aim 1 we will enroll AJ PD with
LRRK2 G2019S mutations, GBA mutations and no mutations, as well as non-manifesting gene carriers, and
non-disease non-mutation controls. This aim will provide precious samples as resource for the Parkinson
Disease Biomarker Program (PDBP) and thus the community, and DNA and RNA for Aims 2 and 3. In Aim 2
we will perform genomic analysis to evaluate pathways implicated in PD. These include genes related to a) PD
and movement disorder-related overlap syndromes, b) lysosomal storage disorders, and c) immune processes.
This aim is primarily exploratory but has great potential as mutations readily identified in this population, such
as GBA, have worldwide disease significance. In Aim 3, our central hypothesis is that the transcriptome of
peripheral monocytes harbors important functional variation that underlies the pathobiology of PD directly or
reflects variation in expression in myeloid cells within the brain, such as microglia, and will evaluate profile
gene expression from specific immune cells. Aim 2 will provide WGS and Aim 3 RNASeq data for the
community. We will use state-of the art bioinformatics techniques to evaluate genomics and transcriptomics
within and across the aims. The translational potential is that blood-based biomarkers could be readily assayed
in the clinic and could also give individual information about subtype of disease thereby enabling direct study of
new targets and improved clinical trial design and likelihood of success. Taken together, this approach holds
great potential for better understanding PD pathogenesis, including illuminating disease pathways a...

## Key facts

- **NIH application ID:** 9917851
- **Project number:** 5U01NS107016-02
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Laurie J. Ozelius
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,241,583
- **Award type:** 5
- **Project period:** 2019-05-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9917851

## Citation

> US National Institutes of Health, RePORTER application 9917851, Dissecting Oligogenic Biomarkers in Ashkenazi Jews with Parkinson Disease (5U01NS107016-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9917851. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*